Adagene Inc. – Filings and Transcripts

NASDAQ: ADAG
Share price (10/6/26): $2.93
Market cap (10/6/26): $194 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 12/31/25 FY 2025

ended 12/31/24 FY 2024

ended 12/31/23 FY 2023

ended 12/31/22 FY 2022

ended 12/31/21 FY 2021

Prospectuses and Registrations Filter

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Prospectus supplement

Shelf registration

Prospectus supplement for primary offering

Ownership Filter

News Filter

Resignation of Officer

Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager

Announces That Third Arc Bio Has Selected First Lead Candidate Under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

Achieves Milestone in Collaboration With Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates

Reports Six Months 2026 Financial Results and Provides Corporate Updates

Proxies

No filings in this category.

Other Filter

Notice of effectiveness

Correspondence with the SEC

Notice of effectiveness

Correspondence with the SEC

Correspondence with the SEC